IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure
This study has been completed.
Sponsor:
University of Minnesota - Clinical and Translational Science Institute
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT01149538
First received: June 21, 2010
Last updated: October 26, 2016
Last verified: October 2016
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if choline bitartrate can be administered daily to children with prenatal alcohol exposure, ages 2.5 to 5, as a potential treatment for brain development and cognitive functioning.
| Condition | Intervention | Phase |
|---|---|---|
| Fetal Alcohol Spectrum Disorders Fetal Alcohol Syndrome Partial Fetal Alcohol Syndrome Alcohol Related Neurodevelopmental Disorder Prenatal Alcohol Exposure | Drug: Choline bitartrate Dietary Supplement: Placebo for choline bitartrate | Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure |
Resource links provided by NLM:
Further study details as provided by University of Minnesota - Clinical and Translational Science Institute:
Primary Outcome Measures:
- Side Effects of Choline Bitartrate [ Time Frame: Baseline, 6 months, & 9 months ]Side effects of choline bitartrate will be monitored by the study physician and the P.I. with physical examinations and telephone contact.
- Mullen Scales of Early Learning - Early Learning Composite [ Time Frame: Baseline and 9 months ]The Mullen Scales of Early Learning is a measure of global cognitive development and is a primary outcome measure. The Early Learning Composite is the total score for this measure. It is a scaled score with a mean of 100 and a standard deviation of 15 (higher scores indicate better global cognitive status; average range is 85-115; Impaired range is 70 or below; full range is typically 50 - 150, although minimum and maximum scores are dependent on age). See the Mullen Scales reference manual for more psychometric details.
Secondary Outcome Measures:
- Elicited Imitation Task Memory [ Time Frame: Baseline, 6 months, and 9 months ]The Elicited Imitation (EI) paradigm (P.J. Bauer, 1989, Dev. Psychology) was used to measure memory in the participants at baseline, 6 months, and 9 months. The measures were items recalled after a delay (delayed items) and pairs of items recalled after a delay (delayed pairs). The sample was split by age in the analysis (young vs. old) as reflected in the outcome data. Outcome data measures included here are the slopes of the regression lines reflecting change over the three timepoints, controlling for immediate memory performance on the EI task.The slopes are given, as opposed to the raw scores, because these were the values used in the growth curve analyses. Details of these analyses are included in Wozniak et al. (2015) AJCN, doi:10.3945/ajcn.114.099168. NOTE that the means presented below represent the simple slopes that estimate the change in task performance (% of items correct) per 6-month unit of time. To estimate change in task performance over 9 months, multiply by 1.5.
- Evoked Response Potentials Microvolts [ Time Frame: Baseline, 6 months, and 9 months ]Evoked response potentials were measured for the memory task. Frontal positive slow-wave potential negative component amplitude data are included.
- Evoked Response Potential - Negative Component Latency [ Time Frame: Baseline, 6 months, and 9 months ]Evoked Response Potential - negative component latency data are included.
| Enrollment: | 60 |
| Study Start Date: | July 2010 |
| Study Completion Date: | September 2014 |
| Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Choline Bitartrate
Choline Bitartrate supplementation
|
Drug: Choline bitartrate
Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
|
|
Placebo Comparator: Placebo
Placebo for choline bitartrate supplementation
|
Dietary Supplement: Placebo for choline bitartrate
Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
|
Eligibility| Ages Eligible for Study: | 2 Years to 5 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Available parent or legal guardian capable of participating in informed consent process
- Documented history of heavy prenatal alcohol exposure (self-report, social service records, or adoption records) or presence of facial dysmorphology characteristic of FASD or both
- Evidence of cognitive deficit in at least one neurocognitive domain
Exclusion Criteria:
- History of neurological condition (ex. epilepsy, cerebral palsy, traumatic brain injury)
- History of medical condition known to affect brain function
- History of other neurodevelopmental disorder (ex. autism, down syndrome)
- History of very low birthweight (<1500 grams)
- History of prenatal exposure to drugs other than alcohol, nicotine, and caffeine
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01149538
Please refer to this study by its ClinicalTrials.gov identifier: NCT01149538
Locations
| United States, Minnesota | |
| University of Minnesota | |
| Minneapolis, Minnesota, United States, 55454 | |
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Investigators
| Principal Investigator: | Jeffrey R Wozniak, Ph.D. | University of Minnesota - Clinical and Translational Science Institute |
| Principal Investigator: | Michael Georgieff, M.D. | University of Minnesota - Clinical and Translational Science Institute |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | University of Minnesota - Clinical and Translational Science Institute |
| ClinicalTrials.gov Identifier: | NCT01149538 History of Changes |
| Other Study ID Numbers: |
0910M73517 R21AA019580 ( U.S. NIH Grant/Contract ) |
| Study First Received: | June 21, 2010 |
| Results First Received: | February 29, 2016 |
| Last Updated: | October 26, 2016 |
Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
|
FASD FAS Alcohol Prenatal Alcohol |
Additional relevant MeSH terms:
|
Syndrome Fetal Alcohol Spectrum Disorders Fetal Diseases Alcohol-Induced Disorders Alcohol-Related Disorders Disease Neurodevelopmental Disorders Pathologic Processes Mental Disorders Pregnancy Complications Substance-Related Disorders Chemically-Induced Disorders Ethanol |
Choline Anti-Infective Agents, Local Anti-Infective Agents Central Nervous System Depressants Physiological Effects of Drugs Lipotropic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Gastrointestinal Agents Lipid Regulating Agents Nootropic Agents |
ClinicalTrials.gov processed this record on August 22, 2017